ACE Inhibitors and ARBs: Shared Benefits, Different Tolerability

Lecture collection · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Use one RAAS blocker for a clear indication, check creatinine and potassium after changes, and distinguish an expected hemodynamic effect from a dangerous reaction.

Block different points in the same pathway. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Block different points in the same pathway. Renin → angiotensin I — Upstream RAAS signal; ACE → angiotensin II — ACE inhibitors interrupt this step; AT₁ receptor signaling — ARBs block the receptor; Pressure and potassium effects — Assess filtration, BP and potassium after changes. Use ACE inhibitor OR ARB for the relevant indication. Bradykinin effects differ between the classes. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Similar pathway, different tolerability

ACE inhibitors reduce angiotensin II formation and increase bradykinin; ARBs block AT1 signaling without the same bradykinin effect. Both reduce efferent arteriolar tone and can lower intraglomerular pressure. Choose by disease indication and tolerance, not a universal class ranking.

Albuminuria creates a kidney indication

KDIGO supports ACE inhibitor or ARB for appropriate CKD with A2/A3 albuminuria, particularly diabetes. Use the highest approved tolerated dose when indicated. Do not combine ACE inhibitor plus ARB; dual blockade increases harm without a routine added clinical benefit.

Check before and after

Measure BP, creatinine, and potassium and review depletion, NSAIDs, diuretics, potassium supplements, and MRA/trimethoprim exposure. Recheck within 2–4 weeks after starting or increasing the dose, earlier when the patient’s clinical risk warrants it.

Interpret a creatinine rise

A hemodynamic rise can occur. If creatinine increases >30% within 4 weeks, investigate volume depletion, intercurrent AKI, NSAIDs, excessive diuresis, or renovascular disease and review the dose. Do not permanently discontinue solely for a small stable expected change.

Distinguish cough from angioedema

Troublesome ACE inhibitor cough may permit an ARB alternative. Lip/tongue/throat swelling requires urgent airway assessment and permanent avoidance of the culprit ACE inhibitor. A history of ACE/ARB-related angioedema also contraindicates sacubitril/valsartan; the transition is not a workaround.

Preserve benefit safely

Address manageable hyperkalemia with cause review and indicated treatment; symptomatic hypotension or uncontrolled potassium may require reduction/holding. Avoid these drugs in pregnancy and arrange a preconception plan. After illness-related interruption, document reassessment and restart responsibility.

Supporting evidence

Continue learning